Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Miyoshi, Toru

Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial. [electronic resource] - Heart and vessels Mar 2014 - 178-85 p. digital

Publication Type: Journal Article; Randomized Controlled Trial

1615-2573

10.1007/s00380-013-0343-0 doi


Adiponectin--blood
Aged
Angina, Stable--blood
Angiotensin II Type 1 Receptor Blockers--therapeutic use
Anti-Inflammatory Agents--therapeutic use
Biomarkers--blood
C-Reactive Protein--metabolism
Coronary Artery Disease--blood
Coronary Vessels--drug effects
Disease Progression
Down-Regulation
Female
Humans
Imidazoles--therapeutic use
Inflammation Mediators--blood
Japan
Male
Middle Aged
Percutaneous Coronary Intervention
Plaque, Atherosclerotic
Prospective Studies
Tetrazoles--therapeutic use
Time Factors
Treatment Outcome
Ultrasonography, Interventional